02.08.23 -- A 3-Stage Framework For Decentralized Trial Maturity

Drug developers often talk about “patient centricity,” but most find it challenging to prioritize a patient-centric research approach in the earlier phases of drug development. A good place to start is by collectively measuring what matters most to patients — and COAs help get us there.

Close cooperation between major global regulatory entities and industry sponsors can help adjust processes to maximize drug development efforts, speed up access to novel therapies, and help control development costs.

Explore how clinical and commercial teams should work together for clinical supply packaging, how the COVID-19 pandemic has changed things, and what to consider when looking for a packaging partner.

Learn how to manage a supply chain through IRT with self-service tools and actionable insights as well as best practices for supply forecasting and overstock management.

China now represents 60% of clinical development in CAR-T therapy development globally: what have we learned to date and where are future opportunities?

Industry experts from Eli Lilly and Cognizant share their perspectives on the process and building blocks of end-to-end clinical development, the essential elements of a unified clinical platform, and the benefits and challenges involved in realizing the vision of a unified clinical platform.

Delve into a brief history of radiopharmaceuticals and discover best practices for planning and executing clinical trials utilizing these novel drugs to treat cancer.

Advarra University is the main hub for the training opportunities to help your team and staff feel confident in navigating the technology in their day-to-day operations.

Cmed is highly experienced in the management of cell and gene therapy clinical trials, whether in oncology, rare diseases, or other therapeutic areas.

Decentralized clinical trials (DCTs) offer clear benefits to patients and the overall success of the trial, but it can be difficult to know how to address this challenge. This three-stage framework approach will enable you to assess your organization’s current clinical trial innovation maturity and build a plan from there.

Todd McGrath, chief operating officer, and Emily McDougal, executive director nurse management, will show you how a decentralized delivery of complex clinical visits benefits your clinical trials, sites, and patients.

Hybrid trials have undergone rapid evolution in the past few years. Examine this evolution, the reasons for confidence and concern, and how they may impact pharmaceutical development in the future.

Two hundred thirty-four individuals involved in clinical supply and operations were surveyed to better understand sponsors’ perspectives on DTP distribution of clinical supplies and interest in using it in their studies.

Our integrated EDC platform, including eConsent, ePRO, RTSM, and DDC, is your gateway to decentralized trials. 

Thermo Fisher Scientific provides scalable, custom, direct-to-patient services that ensure patients receive their medication with controlled and on-time delivery.